Shares of ICU Medical (NASDAQ:ICUI), a medical device company specializing in intravenous treatment solutions, were on the move today following the announcement of a cash and stock deal for Smiths Medical. The market signaled its approval of the pending acquisition by pushing the stock 26.2% higher on Wednesday.
Smiths Medical is a U.S.-based component of Smiths Group (OTC:SMGZY), a British conglomerate that manufactures airport baggage scanners and industrial equipment. Smiths Group’s medical division never quite fit in with the rest of its portfolio, but it should do well in ICU Medical’s hands.
Smiths Medical manufactures dozens of medical products, such as positive airway pressure systems and syringe pumps. With a larger line of related products, ICU Medical can become more of a one-stop shop for busy hospital administrators.
Smiths Group will receive $1.85 billion in cash from ICU Medical, plus 2.5 million newly issued shares. There’s also an extra $100 million in consideration, contingent upon ICU Medical’s stock price averaging $300 per share for a 30-day period over the next three years.
The deal is expected to close before the end of the year. I would be surprised if regulators on either side of the Atlantic tried to block the transaction.
ICU Medical expects adjusted earnings before interest taxes depreciation and amortization from Smiths Medical to come in at around $190 million next year. ICU Medical also thinks it can squeeze out around $50 million a year in cost synergies.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.